List of ImmunityBio patents

List of ImmunityBio patents

List of Cancer Advances patents

List of NewLink Genetics patents

List of Rigel Pharmaceuticals patents

List of companies in Altimeter Capital's investment portfolio

List of Stratedigm, Inc. patents

Patents where

Current Assignee

Name

is

ImmunityBio

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11129850 Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies	Patent 11129850 was granted and assigned to ImmunityBio on September, 2021 by the United States Patent and Trademark Office.		ImmunityBio		United States Patent and Trademark Office	11129850	September 28, 2021
	‌ US Patent 11643452 Fc-epsilon car	Patent 11643452 was granted and assigned to ImmunityBio on May, 2023 by the United States Patent and Trademark Office.		ImmunityBio		United States Patent and Trademark Office	11643452	May 9, 2023
	‌ US Patent 11547727 Chimeric antigen receptor-modified NK-92 cells	Patent 11547727 was granted and assigned to ImmunityBio on January, 2023 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	11547727	January 10, 2023
	‌ US Patent 11230699 Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors	Patent 11230699 was granted and assigned to ImmunityBio on January, 2022 by the United States Patent and Trademark Office.	NantKwest	ImmunityBio		United States Patent and Trademark Office	11230699	January 25, 2022
	‌ US Patent 11207350 Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer	Patent 11207350 was granted and assigned to ImmunityBio on December, 2021 by the United States Patent and Trademark Office.		ImmunityBio		United States Patent and Trademark Office	11207350	December 28, 2021
	‌ US Patent 11213547 Tumoricidal and antimicrobial compositions and methods	Patent 11213547 was granted and assigned to ImmunityBio on January, 2022 by the United States Patent and Trademark Office.		ImmunityBio		United States Patent and Trademark Office	11213547	January 4, 2022
	‌ US Patent 11975027 Tumoricidal and antimicrobial compositions and methods	Patent 11975027 was granted and assigned to ImmunityBio on May, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	11975027	May 7, 2024
	‌ US Patent 12016916 Nant COVID vaccine cross reactivity	Patent 12016916 was granted and assigned to ImmunityBio on June, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	12016916	June 25, 2024
	‌ US Patent 12085571 Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags	Patent 12085571 was granted and assigned to ImmunityBio on September, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	12085571	September 10, 2024
	‌ US Patent 12109238 Chimeric antigen receptor-modified NK-92 cells	Patent 12109238 was granted and assigned to ImmunityBio on October, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	12109238	October 8, 2024
	‌ US Patent 11992504 Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment	Patent 11992504 was granted and assigned to ImmunityBio on May, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	11992504	May 28, 2024
	‌ US Patent 12115191 Methods of treating age-related and inflammatory diseases	Patent 12115191 was granted and assigned to ImmunityBio on October, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	12115191	October 15, 2024
	‌ US Patent 11857620 Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus	Patent 11857620 was granted and assigned to ImmunityBio on January, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	11857620	January 2, 2024
	‌ US Patent 11931382 Generating CIK NKT cells from cord blood	Patent 11931382 was granted and assigned to ImmunityBio on March, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	11931382	March 19, 2024
	‌ US Patent 12064450 Tumoricidal and antimicrobial compositions and methods	Patent 12064450 was granted and assigned to ImmunityBio on August, 2024 by the United States Patent and Trademark Office.	ImmunityBio	ImmunityBio		United States Patent and Trademark Office	12064450	August 20, 2024

15 results

0 selected

15 results

0 selected